Research programme: anti-VEGF therapeutics - Taiwan Liposome Company

Drug Profile

Research programme: anti-VEGF therapeutics - Taiwan Liposome Company

Latest Information Update: 27 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiwan Liposome Company
  • Class Drug conjugates; Gene therapies; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Retinal oedema

Most Recent Events

  • 27 Nov 2014 Discontinued for Retinal oedema in Taiwan (IV, Intravitreous)
  • 21 Jun 2013 Early research in Retinal oedema in Taiwan (Intravitreous, IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top